Active surveillance in men with Gleason 3 + 4 = 7 prostate cancer at diagnosis

A critical question for men with favorable intermediate-risk prostate cancer (based primarily on a Gleason score of 3 + 4 = 7) can often be, “How safe would it be for me to go on active surveillance for a while after initial diagnosis?” … READ MORE …

Is Retzius-sparing radical prostatectomy the surgical wave of the future?

Back in the early 1980s, Dr. Patrick Walsh at the Johns Hopkins Medical Center in Baltimore changed the nature of surgical treatment for prostate cancer when he first started to conduct so-called nerve-sparing radical prostatectomies. … READ MORE …

Updated PIVOT data seem to support recent AUA/ASTRO/SUO guidelines

A new article in this week’s New England Journal of Medicine has given us follow-up data from the PIVOT trial of radical prostatectomy vs. simple observation in treatment of localized prostate cancer. … READ MORE …

Eighth randomized clinical trial of hypofractionated radiation therapy

We now have data from an eighth randomized clinical trial of hypofractionated radiation therapy. There are no surprises: … READ MORE …

Letters to the Editor on interpretation of data from the ProtecT trial

In September last year, Hamdy et al. published the initial results of the ProtecT trial — a trial designed to compare overall outcomes at 10 years among > 1,600 men diagnosed with low- and intermediate-risk, localized prostate cancer and randomized to treatment by surgery, by external beam radiation therapy, or by active monitoring (a very basic form of active surveillance). … READ MORE …

Early chemotherapy in treatment of high-risk and aggressive prostate cancers?

So the results from the CHAARTED and STAMPEDE trials over the past few years have re-ignited debate over the appropriateness of early use of chemotherapy in the treatment of aggressive forms of prostate cancer. … READ MORE …

Body mass index, surgery, and risk for prostate cancer-specific death

It is well understood that there is an association between obesity and future risk for prostate cancer-specific mortality among cancer-free men. What has not been so clear is the relationship between obesity and long-term outcomes, post-treatment, among men diagnosed early with localized disease … READ MORE …